Tadalafil Treatment Delays the Onset of Cardiomyopathy in Dystrophin-Deficient Hearts. - Wikidata - awgldk - TriplyDB

Tadalafil Treatment Delays the Onset of Cardiomyopathy in Dystrophin-Deficient Hearts.

Tadalafil Treatment Delays the Onset of Cardiomyopathy in Dystrophin-Deficient Hearts.

http://www.wikidata.org/entity/Q37240478

about

Cardiac Phosphodiesterases and Their Modulation for Treating Heart Disease.Advances in the Treatment of Duchenne Muscular Dystrophy: New and Emerging Pharmacotherapies.Therapeutic strategies to address neuronal nitric oxide synthase deficiency and the loss of nitric oxide bioavailability in Duchenne Muscular Dystrophy.Pharmacological therapeutics targeting the secondary defects and downstream pathology of Duchenne muscular dystrophy Disease-modifying effects of orally bioavailable NF-κB inhibitors in dystrophin-deficient muscle A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy.Micro-utrophin Improves Cardiac and Skeletal Muscle Function of Severely Affected D2/ Mice

P2860

Q38992600-738E3BE5-73D7-4A86-AEBC-BD391407E57A Q39115626-B646A9C3-C103-498A-A876-4F9674BAEBBA Q39330717-E0BAFD72-F28D-49E9-B86A-8AF89ED47B55 Q39410461-48DAFB28-33BE-4335-AC73-242B3E6D8B89 Q42350965-4E8200C3-DC71-48F6-883F-EFB9C4CB1086 Q46262285-E5E08DD2-2AE6-4514-B1A8-CD740EFF961D Q58730294-901823EE-83EB-4002-A07C-16C1ADDB0212

P2860

Tadalafil Treatment Delays the Onset of Cardiomyopathy in Dystrophin-Deficient Hearts.

http://www.wikidata.org/entity/Q37240478

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 09 August 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Tadalafil Treatment Delays the Onset of Cardiomyopathy in Dystrophin-Deficient Hearts.

@en

Tadalafil Treatment Delays the Onset of Cardiomyopathy in Dystrophin-Deficient Hearts.

@nl

type

label

Tadalafil Treatment Delays the Onset of Cardiomyopathy in Dystrophin-Deficient Hearts.

@en

Tadalafil Treatment Delays the Onset of Cardiomyopathy in Dystrophin-Deficient Hearts.

@nl

prefLabel

Tadalafil Treatment Delays the Onset of Cardiomyopathy in Dystrophin-Deficient Hearts.

@en

Tadalafil Treatment Delays the Onset of Cardiomyopathy in Dystrophin-Deficient Hearts.

@nl

P1433

Q37240478-103CA18D-3016-4801-8BF4-5E48B4393675

P1476

Q37240478-98D2E7CC-B760-4E09-ACED-672190E7E6B4

P2093

Q37240478-649037FE-7F50-43DB-B49F-435F422389A6

Q37240478-7E1A009B-6131-47C8-802D-F895801AEA8E

Q37240478-A52993A0-95E5-4DAB-8F16-ACCDB8AB3420

Q37240478-B14E2472-AE13-4ACA-91B4-540F43C88831

Q37240478-BFDE34E2-6715-407C-A577-7D91406A7FB3

Q37240478-DA9B301D-485A-4428-A6B4-FB323EB5590B

P2860

Q37240478-07FBDF95-8FD0-436C-A6B0-62484064542A

Q37240478-0B796DC4-F7DA-47DC-99B0-0F6B3E326A61

Q37240478-0DAFBE46-968C-4A19-A9D6-DBC55226B552

Q37240478-1428E4A0-AAF3-47C2-A0D8-1A8A97ABA7D4

Q37240478-160E5B09-2F0C-4AFE-88BD-7D38253A8DC2

Q37240478-1ED4D3EB-E7E5-4673-8D21-3FE98167283F

Q37240478-1F073D3E-3D15-4FB6-B923-F8EC9B608901

Q37240478-274755BF-6FF9-41EE-B60B-83FAB5405410

Q37240478-2CEE3EC3-FECF-44E3-A4F8-92C020930057

Q37240478-2D42751A-91B6-41ED-A77F-960760E7547C

P31

Q37240478-B9E2628E-23E6-4DFA-88A0-9DBAA7AAF301

P356

Q37240478-226207CE-5B55-44D4-8230-A8E472D7B6AB

P433

Q37240478-7B233A4D-1732-462E-A1AA-A1E0894481B0

P478

Q37240478-7DF3462C-E349-4F98-90DF-371541687AD5

P577

Q37240478-FCB9ABB7-AE2F-4D27-96C1-9956BB9C490E

P698

Q37240478-96019428-5222-4AFB-841A-7C09B5987C57

P932

Q37240478-19AFFE4C-E509-4FD7-A965-CEA980AA3E8E

P356

JAHA.116.003911

P1433

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

P1476

Tadalafil Treatment Delays the Onset of Cardiomyopathy in Dystrophin-Deficient Hearts.

@en

P2093

Ai Shima

http://www.w3.org/2001/XMLSchema#string

David W Hammers

http://www.w3.org/2001/XMLSchema#string

Glenn A Walter

http://www.w3.org/2001/XMLSchema#string

H Lee Sweeney

http://www.w3.org/2001/XMLSchema#string

Margaret M Sleeper

http://www.w3.org/2001/XMLSchema#string

Sean C Forbes

http://www.w3.org/2001/XMLSchema#string

P2860

Sildenafil and cardiomyocyte-specific cGMP signaling prevent cardiomyopathic changes associated with dystrophin deficiency

Primary role of functional ischemia, quantitative evidence for the two-hit mechanism, and phosphodiesterase-5 inhibitor therapy in mouse muscular dystrophy

PDE5A suppression of acute beta-adrenergic activation requires modulation of myocyte beta-3 signaling coupled to PKG-mediated troponin I phosphorylation.

Cyclic GMP/PKG-dependent inhibition of TRPC6 channel activity and expression negatively regulates cardiomyocyte NFAT activation Novel mechanism of cardiac stress modulation by PDE5 inhibition

Chronic administration of membrane sealant prevents severe cardiac injury and ventricular dilatation in dystrophic dogs.

Phosphorylation of TRPC6 channels at Thr69 is required for anti-hypertrophic effects of phosphodiesterase 5 inhibition

Translocation and cleavage of myocardial dystrophin as a common pathway to advanced heart failure: a scheme for the progression of cardiac dysfunction

PDE5 inhibition alleviates functional muscle ischemia in boys with Duchenne muscular dystrophy.

Oxidative stress regulates left ventricular PDE5 expression in the failing heart

Sildenafil reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy.

P31

scholarly article

P356

10.1161/JAHA.116.003911

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2016-08-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27506543

http://www.w3.org/2001/XMLSchema#string

P932

5015305

http://www.w3.org/2001/XMLSchema#string